Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis-Reference-Cited by-同舟云学术

Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis

Published:2021-11-25 Issue:11 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Walter Martin A¹,Nesti Cédric²,Spanjol Marko¹,Kollár Attila³,Bütikofer Lukas⁴,Gloy Viktoria L⁵,Dumont Rebecca A¹,Seiler Christian A²,Christ Emanuel R⁶,Radojewski Piotr¹,Briel Matthias⁵,Kaderli Reto M²

Affiliation:

1. Nuclear Medicine Division, Diagnostic Department; University Hospitals Geneva (HUG); Geneva Switzerland

2. Department of Visceral Surgery and Medicine; Bern University Hospital, University of Bern; Bern Switzerland

3. Department of Medical Oncology; Bern University Hospital, University of Bern; Bern Switzerland

4. Clinical Trials Unit, Bern, University of Bern; Bern Switzerland

5. Department of Clinical Research; University Hospital Basel and University of Basel; Basel Switzerland

6. Department of Endocrinology, Diabetes, and Metabolism; Basel University Hospital, University of Basel; Basel Switzerland

Publisher

Wiley

Subject

Pharmacology (medical)

Reference166 articles.

1. Impact of prior somatostatin analog use on PFS in the phase III radiant-2 trial of everolimus + octreotide lar vs placebo + octreotide lar in patients with advanced neuroendocrine tumors;Anthony;Pancreas,2012

2. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study;Pavel;Lancet,2012

3. Efficacy of octreotide long-acting repeatable (OCT) from the phase III RADIANT-2 study in patients with advanced neuroendocrine tumors (NET): A post-hoc analysis of the placebo (PBO) arm with updated survival data;Strosberg;Pancreas,2015

4. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial;Arnold;Clinical Gastroenterolology and Hepatolology,2005

5. Randomized phase II trial of pazopanib versus placebo in patients (Pts) with progressive carcinoid tumors (CARC) (Alliance A021202);Bergsland;Pancreas,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How do different therapies compare with placebo and with each other in people with gastrointestinal neuroendocrine tumors (gNETs)?;Cochrane Clinical Answers;2022-07-27

2. How do different therapies compare with placebo and with each other in people with pancreatic neuroendocrine tumors (pNETs)?;Cochrane Clinical Answers;2022-07-27